Ashleigh Xie1, Kevin Phan1, Yi-Chin Tsai2, Tristan D Yan3, Paul Forrest4. 1. The Collaborative Research (CORE) Group, Macquarie University, Sydney, Australia; University of New South Wales, Sydney, Australia. 2. Department of Cardiothoracic Surgery, Prince Charles Hospital, Brisbane, Australia. 3. The Collaborative Research (CORE) Group, Macquarie University, Sydney, Australia; Department of Cardiothoracic Surgery; University of Sydney, Sydney, Australia. Electronic address: tristanyan@annalscts.com. 4. Cardiothoracic Anesthesia and Perfusion, Royal Prince Alfred Hospital, Sydney, Australia; University of Sydney, Sydney, Australia.
Abstract
OBJECTIVE: To evaluate the effect of extracorporeal membrane oxygenation (ECMO) on survival and complication rates in adults with refractory cardiogenic shock or cardiac arrest. DESIGN: Meta-analysis. SETTING: University hospitals. PARTICIPANTS: One thousand one hundred ninety-nine patients from 22 observational studies. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Observational studies published from the year 2000 onwards, examining at least 10 adult patients who received ECMO for refractory cardiogenic shock or cardiac arrest were included. Pooled estimates with 95% confidence intervals were calculated based on the Freeman-Tukey double-arcsine transformation and DerSimonian-Laird random-effect model. Survival to discharge was 40.2% (95% confidence intervals [CI], 33.9-46.7), while survival at 3, 6, and 12 months was 55.9% (95% CI, 41.5-69.8), 47.6% (95% CI, 25.4-70.2), and 54.4% (95% CI, 36.6-71.7), respectively. Survival up to 30 days was higher in cardiogenic shock patients (52.5%, 95% CI, 43.7%-61.2%) compared to cardiac arrest (36.2%, 95% CI, 23.1%-50.4%). Concurrently, complication rates were particularly substantial for neurologic deficits (13.3%, 95% CI, 8.3-19.3), infection (25.1%, 95%CI, 15.9-35.5), and renal impairment (47.4%, 95% CI, 30.2-64.9). Significant heterogeneity was detected, although its levels were similar to previous meta-analyses that only examined short-term survival to discharge. CONCLUSIONS: Venoarterial ECMO can improve short-term survival in adults with refractory cardiogenic shock or cardiac arrest. It also may provide favorable long-term survival at up to 3 years postdischarge. However, ECMO also is associated with significant complication rates, which must be incorporated into the risk-benefit analysis when considering treatment. These findings require confirmation by large, adequately controlled and standardized trials with long-term follow-up.
OBJECTIVE: To evaluate the effect of extracorporeal membrane oxygenation (ECMO) on survival and complication rates in adults with refractory cardiogenic shock or cardiac arrest. DESIGN: Meta-analysis. SETTING: University hospitals. PARTICIPANTS: One thousand one hundred ninety-nine patients from 22 observational studies. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Observational studies published from the year 2000 onwards, examining at least 10 adult patients who received ECMO for refractory cardiogenic shock or cardiac arrest were included. Pooled estimates with 95% confidence intervals were calculated based on the Freeman-Tukey double-arcsine transformation and DerSimonian-Laird random-effect model. Survival to discharge was 40.2% (95% confidence intervals [CI], 33.9-46.7), while survival at 3, 6, and 12 months was 55.9% (95% CI, 41.5-69.8), 47.6% (95% CI, 25.4-70.2), and 54.4% (95% CI, 36.6-71.7), respectively. Survival up to 30 days was higher in cardiogenic shockpatients (52.5%, 95% CI, 43.7%-61.2%) compared to cardiac arrest (36.2%, 95% CI, 23.1%-50.4%). Concurrently, complication rates were particularly substantial for neurologic deficits (13.3%, 95% CI, 8.3-19.3), infection (25.1%, 95%CI, 15.9-35.5), and renal impairment (47.4%, 95% CI, 30.2-64.9). Significant heterogeneity was detected, although its levels were similar to previous meta-analyses that only examined short-term survival to discharge. CONCLUSIONS: Venoarterial ECMO can improve short-term survival in adults with refractory cardiogenic shock or cardiac arrest. It also may provide favorable long-term survival at up to 3 years postdischarge. However, ECMO also is associated with significant complication rates, which must be incorporated into the risk-benefit analysis when considering treatment. These findings require confirmation by large, adequately controlled and standardized trials with long-term follow-up.
Authors: Rahul S Loungani; Marat Fudim; Dave Ranney; Ajar Kochar; Marc D Samsky; Desiree Bonadonna; Akinobu Itoh; Hiroo Takayama; Koji Takeda; Daniel Wojdyla; Adam D DeVore; Mani Daneshmand Journal: J Card Fail Date: 2021-01-13 Impact factor: 5.712
Authors: Marc Pineton de Chambrun; Nicolas Bréchot; Guillaume Lebreton; Matthieu Schmidt; Guillaume Hekimian; Pierre Demondion; Jean-Louis Trouillet; Pascal Leprince; Jean Chastre; Alain Combes; Charles-Edouard Luyt Journal: Intensive Care Med Date: 2016-09-28 Impact factor: 17.440
Authors: Roberto Lorusso; Giuseppe Maria Raffa; Khalid Alenizy; Niels Sluijpers; Maged Makhoul; Daniel Brodie; Mike McMullan; I-Wen Wang; Paolo Meani; Graeme MacLaren; Mariusz Kowalewski; Heidi Dalton; Ryan Barbaro; Xiaotong Hou; Nicholas Cavarocchi; Yih-Sharng Chen; Ravi Thiagarajan; Peta Alexander; Bahaaldin Alsoufi; Christian A Bermudez; Ashish S Shah; Jonathan Haft; David A D'Alessandro; Udo Boeken; Glenn J R Whitman Journal: J Heart Lung Transplant Date: 2019-08-10 Impact factor: 10.247
Authors: Prakash Acharya; William A Jakobleff; Stephen J Forest; Thiru Chinnadurai; Nicolas Mellas; Snehal R Patel; Jorge R Kizer; Henny H Billett; Daniel J Goldstein; Ulrich P Jorde; Omar Saeed Journal: ASAIO J Date: 2020-03 Impact factor: 3.826
Authors: Dagmar M Ouweneel; Jasper V Schotborgh; Jacqueline Limpens; Krischan D Sjauw; A E Engström; Wim K Lagrand; Thomas G V Cherpanath; Antoine H G Driessen; Bas A J M de Mol; José P S Henriques Journal: Intensive Care Med Date: 2016-09-19 Impact factor: 17.440